Latest Adjuvant Stories

LONDON, April 9, 2013 /PRNewswire/ -- Bioradar UK Ltd and Replikins Ltd announced today that a new completely synthetic H7N9 Replikins Vaccine is ready for testing. The news comes on the heels of four new cases of avian flu (H7N9) reported in China, bringing the total to 28 cases, 8 of whom have died from the virus. The new vaccine is produced without any biological substances and will be used without adjuvants, similar to the H5N1 Synthetic Replikins Vaccine which was found...

Aluminum salts, or alum, have been injected into billions of people as an adjuvant to make vaccines more effective. No one knows, however, how they boost the immune response. In the March 19, 2013, issue of the Proceedings of the National Academy of Sciences researchers at National Jewish Health continue unraveling the mystery of adjuvants with a report that host DNA coats the alum adjuvant and induces two crucial cells to interact twice as long during the initial stimulation of the adaptive...

Connie K. Ho for redOrbit.com – Your Universe Online Scientists from the University of Texas-Austin (UTA) recently revealed that they have been able to develop 61 new strains of genetically engineered bacteria that could boost the effectiveness of vaccines for diseases such as cholera, HPV, the flu, and pertussis. The findings on these strains of E. coli were featured in a recent edition of the Proceedings of the National Academy of Sciences. These strains of E. coli are part of a new...

ITTIGEN, Switzerland, November 8, 2012 /PRNewswire/ -- - Patent already granted in Europe - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of...

Novel vaccine additive to enhance the body's immune response shows promise in mice Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice. An 'adjuvant' is a substance added to a vaccine to enhance the immune response and offer better protection against infection. The Oxford University team, along with Swedish and US colleagues, have shown that a type of polymer called polyethyleneimine (PEI)...

TERRE HAUTE, Ind., Jan. 13, 2012 /PRNewswire-USNewswire/ -- While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395."I'm so excited," said Ghosh, Indiana State University professor of biology, about the completion of the process that began in 2006. The patent is in place for 24 years and the university will now begin marketing it to pharmaceutical...

SEATTLE, Jan. 7, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) today announced it has received a multi-million dollar grant from the Defense Advanced Research Projects Agency (DARPA), and the Army Research Office (ARO), both parts of United States Department of Defense. This new funding will support IDRI's development of a single dose influenza vaccine to be widely administered in case of pandemic flu outbreak. The proposal combines cutting-edge vaccine...

SEATTLE, Dec. 4, 2010 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency. "BARDA is supporting an important expansion of IDRI's technology to solutions...

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC's proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases. "We are pleased to enter into this license with MedImmune as one of the...

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.The University of Rochester Medical Center has applied for international...